Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:1 - 21
Updated:11/23/2013
Start Date:June 2010

Use our guide to learn which trials are right for you!

A Phase 1 Study of Temsirolimus in Combination With Irinotecan and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors


This phase I trial is studying the side effects and the best dose of temsirolimus when given
together with irinotecan hydrochloride and temozolomide in treating younger patients with
recurrent or refractory solid tumors. Temsirolimus may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Giving
temsirolimus together with combination chemotherapy may kill more tumor cells.


PRIMARY OBJECTIVES:

I. To estimate the maximum tolerated dose (MTD) or recommended Phase 2 dose and schedule of
temsirolimus administered in combination with irinotecan and temozolomide every three weeks
to children with recurrent or refractory solid tumors.

II. To define and describe the toxicities of this regimen in these patients.

SECONDARY OBJECTIVES:

I. To preliminarily define the antitumor activity of this regimen in these patients.

II. To collect preliminary data regarding the biologic effects of temsirolimus on proteins
involved in signaling pathways of interest in these patients. (Exploratory)

OUTLINE: This is a multicenter study, dose-escalation study of temsirolimus.

Patients receive temsirolimus IV over 30 minutes on days 1 and 8 or on days 1, 8, and 15 and
irinotecan hydrochloride and oral temozolomide on days 1-5. Courses repeat every 21 days for
up to 12 months in the absence of disease progression or unacceptable toxicity.

Some patients undergo bone marrow collection at baseline and during study for
temsirolimus-induced changes in mTOR pathway proteins by flow cytometric analysis and
immunoblotting.

After completion of study therapy, patients are followed up for 30 days.

Inclusion Criteria:

- Histologically confirmed solid tumor at original diagnosis or relapse except for the
following, which do not require biopsies:

- Intrinsic brain stem tumors

- Optic pathway gliomas

- Pineal tumors with elevations of serum, CSF alpha-fetoprotein, or beta-HCG

- Recurrent or refractory disease

- Measurable or evaluable disease

- Disease for which there is no known curative therapy or therapy proven to prolong
survival with an acceptable quality of life

- Patients with CNS tumors must have been relatively stable for ≥ 1 week

- Karnofsky performance status (PS) 50-100% (patients > 16 years of age) OR Lansky PS
50-100% (patients ≤ 16 years of age)

- ANC ≥ 1,000/mm^3

- Platelet count ≥ 100,000/mm^3 (transfusion independent)

- Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR a serum creatinine based on
age and/or gender as follows:

- ≤ 0.6 mg/dL (1 to < 2 years of age)

- ≤ 0.8 mg/dL (2 to < 6 years of age)

- ≤ 1.0 mg/dL (6 to < 10 years of age)

- ≤ 1.2 mg/dL (10 to < 13 years of age)

- ≤ 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to < 16 years of age)

- ≤ 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- ALT ≤ 110 U/L

- Serum albumin > 2 g/dL

- PT < 1.2 times ULN

- Serum triglycerides ≤ 300 mg/dL

- Serum cholesterol ≤ 300 mg/dL

- Random or fasting blood glucose normal

- Normal pulmonary function tests, including DLCO, if clinically indicated (e.g.,
dyspnea at rest, known requirement for supplemental oxygen)

- Patients with seizure disorder allowed provided it is well controlled with
non-enzyme-inducing anticonvulsants

- Nervous system disorders resulting from prior therapy ≤ grade 2

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No uncontrolled infection

- No patients who, in the opinion of the investigator, may not be able to comply with
the safety monitoring requirements of the study

- No history of allergic reactions attributed to compounds of similar composition to
irinotecan hydrochloride, temozolomide, or temsirolimus

- No evidence of graft-vs-host disease

- Fully recovered from all prior anticancer therapy

- More than 3 weeks since prior myelosuppressive therapy (6 weeks for nitrosourea)

- At least 14 days since prior long-acting growth factor (e.g., Neulasta) OR 7 days for
short-acting growth factor

- At least 7 days since prior biologic agent that is not a monoclonal antibody (e.g.,
platelet infusions)

- At least 6 weeks since prior immunotherapies (e.g., tumor vaccines)

- At least 3 half-lives since prior monoclonal antibody therapy

- At least 2 weeks since prior local palliative radiotherapy (small port)

- At least 24 weeks since prior total-body irradiation, craniospinal radiotherapy
(RT), or RT to ≥ 50% to the pelvis

- At least 6 weeks since prior substantial bone marrow RT

- At least 12 weeks since prior stem cell transplantation or stem cell infusion without
RT

- Prior irinotecan hydrochloride, temozolomide, and temsirolimus as single agents or a
combination of 2 of the 3 drugs, including irinotecan hydrochloride and temozolomide,
allowed

- No prior combination of the 3 agents

- Concurrent corticosteroids allowed provided dose has been stable or decreasing for 7
days

- Intermittent use of corticosteroids to manage infusional reactions is allowed

- More than 6 weeks since prior major surgery

- Recent minor surgical procedures (e.g., vascular catheter placement, bone marrow
evaluation, or laparoscopic surgery) allowed

- No other concurrent investigational drugs

- No other concurrent anticancer agents, including chemotherapy, RT, immunotherapy, or
biologic therapy

- No concurrent enzyme-inducing anticonvulsants

- No concurrent CYP3A4 inducers or inhibitors including any of the following:

- Erythromycin

- Clarithromycin

- Ketoconazole

- Azithromycin

- Itraconazole

- Grapefruit juice

- St. John wort

- No concurrent therapeutic anticoagulants, including aspirin or low molecular weight
heparin

- No concurrent angiotensin-converting enzyme (ACE) inhibitors

- No concurrent cyclosporine, tacrolimus, or other agents to prevent either
graft-versus-host disease post-bone marrow transplant or organ rejection
post-transplant
We found this trial at
23
sites
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials
1600 7th Avenue
Birmingham, Alabama 35233
(205) 638-9100
Children's Hospital of Alabama Children
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
(714) 997-3000
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
?
mi
from
Orange, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
1540 East Hospital Drive
Ann Arbor, Michigan 48109
(877) 475-6688
C S Mott Children's Hospital Behind the doors of C.S. Mott Children's Hospital there exist...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Arcadia, California 91006
?
mi
from
Arcadia, CA
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chicago, Illinois 60614
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
705 Riley Hospital Dr
Indianapolis, Indiana 46202
(317) 944-5000
Riley Hospital for Children Riley Hospital for Children at IU Health is a place of...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Milwaukee, Wisconsin 53226
Midwest Children's Cancer Center The Medical College of Wisconsin Cancer Center is dedicated to providing...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
2450 Riverside Ave
Minneapolis, Minnesota 55454
(612) 273-3000
University of Minnesota Medical Center, Fairview Improving patients' lives drives the innovation that makes University...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
505 Parnassus Ave
San Francisco, California 94143
(415) 476-1000
University of California, San Francisco Medical Center UCSF Medical Center is recognized throughout the world...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
?
mi
from
Seattle, WA
Click here to add this to my saved trials